Shopping Cart
- Remove All
Your shopping cart is currently empty
Carteolol hydrochloride (Abbott-43326) is a synthetic quinolinone derivative, antihypertensive Carteolol Hydrochloride is a nonselective beta-adrenoceptor blocking agent for beta-1 and beta-2 receptors with no membrane-stabilizing activity but moderate intrinsic sympathomimetic effects. It is used for the treatment of hypertension and certain arrhythmias and as an anti-angina and antiglaucoma agent.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 10 mg | $31 | In Stock | |
| 25 mg | $48 | In Stock | |
| 50 mg | $72 | In Stock | |
| 100 mg | $113 | In Stock | |
| 200 mg | $168 | In Stock | |
| 500 mg | $282 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $50 | In Stock |
| Description | Carteolol hydrochloride (Abbott-43326) is a synthetic quinolinone derivative, antihypertensive Carteolol Hydrochloride is a nonselective beta-adrenoceptor blocking agent for beta-1 and beta-2 receptors with no membrane-stabilizing activity but moderate intrinsic sympathomimetic effects. It is used for the treatment of hypertension and certain arrhythmias and as an anti-angina and antiglaucoma agent. |
| Targets&IC50 | H2O2-induced cell damage:48 mmol/L |
| Synonyms | OPC-1085 hydrochloride, Mikelan, Carteolol HCl, Arteoptic, Abbott-43326 |
| Molecular Weight | 328.83 |
| Formula | C16H24N2O3·HCl |
| Cas No. | 51781-21-6 |
| Smiles | Cl.CC(C)(C)NCC(O)COc1cccc2NC(=O)CCc12 |
| Relative Density. | 1.13g/cm3 |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 18.33 mg/mL (55.75 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2.5 mg/mL (7.6 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.